Progress and Challenges in Alzheimer’s Disease Drug Development: An Update on Scientific, Clinical, and Regulatory Considerations from an Industry Perspective

The Global CEO Initiative on Alzheimer’s Disease released “Progress and Challenges in Alzheimer’s Disease Drug Development:  An Update on Scientific, Clinical and Regulatory Considerations from an Industry Perspective.”  This paper provides an update to the 2016 paper and provides recommendations to increase the speed of drug development for those impacted by Alzheimer’s disease.

Read the White Paper Here